Menopause & Weight Loss
Mounjaro for Menopause: Weight Gain, HRT and Safety
Quick Answer: Mounjaro is not licensed to treat menopause symptoms. However, it may be prescribed for weight management during or after menopause when a woman meets the usual eligibility criteria. It can reduce appetite and support clinically meaningful weight loss, although trials have not shown a unique effect on menopause-related weight gain. In SURMOUNT-1, 67.5% of participants were women and the mean age was 45; average weight loss at 15 mg was 20.9% over 72 weeks across the full study group. HRT, oral contraception, pregnancy plans and other medicines should be reviewed before starting the Mounjaro weight loss injection.20.9%average weight loss at 15 mg over 72 weeks in SURMOUNT-1
67.5%of SURMOUNT-1 participants were women
4 weeksadditional contraception advised after starting and after each dose increase
Content last updated: 8 October 2026
The Biology
Why Weight Can Change During Menopause
The menopause transition is associated with changes in body composition and a greater tendency to store fat around the abdomen. Ageing can also reduce muscle mass and daily energy needs, while poor sleep, hot flushes, stress, medicines and changes in activity may influence eating and weight.
These factors vary between individuals. Menopause is not the only possible explanation for weight gain, and it does not mean that conventional lifestyle measures cannot help. Our guide to Mounjaro benefits for women over 40 explains the wider evidence and safety considerations.
Fat distributionFalling oestrogen is associated with increased central and visceral fat, even when overall weight changes are modest.
Muscle and ageingGradual loss of lean mass can reduce energy needs. Resistance exercise and adequate protein remain important.
Sleep and symptomsSleep disruption and low mood can indirectly affect appetite, activity and food choices, but experiences differ.
Appetite & Routine
How Menopause Can Affect Eating Patterns
Menopause does not produce one predictable appetite pattern. Some women notice more hunger or cravings, while others mainly find that poor sleep, stress or fatigue make regular meals and activity harder to maintain. If sleep changes after starting treatment, our guide to Mounjaro sleep issues explains possible causes and when to ask for help.
Mounjaro reduces appetite and increases feelings of fullness through GIP and GLP-1 receptor activity. This action is not specific to menopause. A sustainable eating pattern still matters, particularly when appetite is low enough to make protein, fluids or micronutrients difficult to obtain.
Practical focus: Build meals around protein, vegetables or fruit, fibre-rich carbohydrates and enough fluid. Our guide to what to eat on Mounjaro includes practical meal and nausea-management advice.
Sustainable Weight Management
Why Weight Loss May Feel Harder During Menopause
Weight management may feel harder when sleep, mood, hot flushes, joint pain or caring responsibilities make consistent routines difficult. Restrictive diets can also be hard to maintain and may not provide enough protein or other nutrients.
Mounjaro can make a calorie deficit easier by reducing hunger, but it does not remove the need for an appropriate diet, physical activity and ongoing clinical review. The aim is a sustainable plan that protects health and lean mass rather than the fastest possible loss.
Menopause care still matters: Mounjaro does not replace treatment for hot flushes, night sweats, mood changes, vaginal symptoms or osteoporosis risk. Discuss these symptoms separately with a GP or menopause clinician.
How Treatment Works
How Mounjaro Works During Menopause
Mounjaro contains tirzepatide, which activates GIP and GLP-1 receptors. It reduces appetite, increases fullness and improves glucose-dependent insulin secretion. The medicine works through the same mechanisms whether or not a patient is in menopause.
Mounjaro and Wegovy have different active ingredients and trial results. Neither is automatically right for every menopausal woman; see our Mounjaro vs Wegovy comparison. The evidence and HRT considerations for Wegovy for menopause weight gain are explained separately.
Reduced appetiteMany people find smaller portions more satisfying, which can support a sustained calorie deficit.
Slower gastric emptyingFood leaves the stomach more slowly, particularly after treatment starts. This also matters for some oral medicines.
Glucose regulationTirzepatide improves glucose-dependent insulin signalling; individual metabolic effects vary.
Clinical Evidence
What the Tirzepatide Evidence Shows
SURMOUNT-1 studied 2,539 adults with obesity, or overweight with at least one weight-related condition, without diabetes. The mean age was 45 and 67.5% of participants were women. Results were reported for the overall groups rather than specifically for menopausal women.
| Study group | Average weight change at 72 weeks | How to interpret it |
|---|---|---|
| Tirzepatide 5 mg | 15.0% reduction | Overall trial average, not menopause-specific |
| Tirzepatide 10 mg | 19.5% reduction | Overall trial average, not menopause-specific |
| Tirzepatide 15 mg | 20.9% reduction | Overall trial average, not menopause-specific |
| Placebo | 3.1% reduction | All groups also received lifestyle support |
Results vary: Trial averages are not a prediction for an individual. Dose, tolerability, health conditions, adherence and lifestyle support all affect outcomes.
Potential Benefits
Potential Benefits Beyond Scale Weight
Clinically meaningful weight loss may improve waist circumference and some weight-related risk factors. It may also make movement easier for some people. These are possible consequences of weight loss and metabolic improvement; Mounjaro is not a direct treatment for menopause symptoms.
Waist circumferenceThe SURMOUNT programme reported meaningful average reductions in waist circumference across the overall population.
Weight-related healthBlood pressure, glucose and other markers may improve as weight falls, but monitoring remains individual.
Everyday functionSome people find activity easier after weight loss; this should not be promised as a treatment effect for menopause symptoms.
Treatment & Safety
What to Expect When Starting Mounjaro
Menopause on its own does not make someone eligible for treatment. A prescriber should assess BMI, weight-related health conditions, medical history, current medicines and whether Mounjaro can be used safely.
Treatment usually starts at 2.5 mg once weekly and increases gradually when appropriate. The highest dose is not necessary or suitable for everyone; see the Mounjaro dose schedule for the usual UK titration steps.
Common reactions include nausea, diarrhoea, vomiting, abdominal pain and constipation. Read our Mounjaro side effects guide and contact a clinician if symptoms are severe, persistent or prevent adequate fluid intake.
Hair shedding can have several possible causes during menopause and weight loss. Our Mounjaro hair loss guide explains what the evidence shows, what may contribute and when to seek medical advice.
HRT and oral medicines: British Menopause Society guidance highlights concern that delayed gastric emptying could affect absorption of oral HRT, particularly oral progestogens used to protect the womb lining. Ask the clinician managing your HRT to review the formulation and dose. Do not change HRT without medical advice.
Pregnancy and contraception: Mounjaro should not be used during pregnancy and should be stopped at least one month before a planned pregnancy. If you use oral contraception, UK prescribing information advises a barrier method or non-oral contraception for four weeks after starting and for four weeks after each dose increase. Read our Mounjaro and the contraceptive pill guide for practical details.
Key Questions
Mounjaro for Menopause: Key Questions Answered
Can Mounjaro help with menopause weight gain?
It can support weight loss in an eligible woman who is going through menopause, but the evidence does not show that it treats menopause-related weight gain through a unique mechanism. Standard prescribing criteria and individual assessment still apply.
Can Mounjaro reduce menopause belly fat?
Mounjaro cannot target fat from one area. Weight loss may reduce waist circumference and visceral fat, but the amount and location of change vary. Resistance exercise and adequate protein can help protect lean mass; see our Mounjaro muscle-loss guide.
Does Mounjaro treat menopause symptoms?
No. It is a weight-management medicine and does not treat hot flushes, night sweats, vaginal symptoms or other core menopause symptoms. Those concerns need appropriate menopause assessment and treatment.
FAQs
Frequently Asked Questions: Mounjaro and Menopause
Mounjaro can support weight loss when a woman meets the licensed eligibility criteria, whether or not she is in menopause. Trials have not established a unique menopause-specific benefit, and treatment does not replace care for menopause symptoms.
They may be used together following clinical review. British Menopause Society guidance recommends reviewing oral HRT because delayed gastric emptying may affect absorption, particularly of oral progestogens. Ask the clinician managing your HRT before changing any formulation or dose.
Tirzepatide reduces body weight and waist circumference on average, but it cannot target fat from one body area and individual results vary. The evidence does not support promising a specific menopause-belly-fat result.
Reduced effectiveness of oral contraception cannot be excluded in women with overweight or obesity. Use a barrier method or switch to non-oral contraception for four weeks after starting Mounjaro and for four weeks after each dose increase, following prescriber advice.
Mounjaro should not be used during pregnancy. UK prescribing information says tirzepatide should be stopped at least one month before a planned pregnancy. Speak to your prescriber before stopping or changing treatment.
Head-to-head evidence found greater average weight loss with tirzepatide than semaglutide in the overall study population. It did not prove a special advantage specifically during menopause, so suitability depends on medical history, side effects, previous response and prescribing assessment.
Ready to Start Mounjaro Treatment?
GPhC-registered pharmacy (No. 9013192) · UK-licensed prescribers · Free online assessment · Superintendent Pharmacist: Palvinder Deol · Trustpilot 4.8 ★
Start Your Assessment →
References
1. Electronic Medicines Compendium. Mounjaro Summary of Product Characteristics and Patient Information Leaflet. Read the UK prescribing information.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity, SURMOUNT-1. Read the PubMed abstract.
3. British Menopause Society. Guidance on incretin-based therapies in women using HRT.
4. NICE TA1026. Tirzepatide for managing overweight and obesity. Read the NICE guidance.
Educational information only. Individual clinical assessment is required.
Medically Reviewed by Our GPhC-Registered Pharmacists
